<DOC>
	<DOC>NCT00975715</DOC>
	<brief_summary>This study is designed to provide short term efficacy and safety data of TRI476 in children with inadequately-controlled partial seizures. Patients will be randomized into either drug treatment or placebo group at 1:1 ratio, and receive their respective treatment for 8 weeks. The purpose of study is to confirm that TRI476 as adjunctive therapy is effective and safe.</brief_summary>
	<brief_title>Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Oxcarbazepine</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>Male and female outpatients, aged 4 to 14 years (inclusive), with a minimum body weight of 15 kg. A diagnosis of partial onset seizures, which include the seizure subtypes of simple, complex, and secondarily generalized seizures (based on the International League Against Epilepsy (ILAE) Classification, as modified in 1981). A document history of generalized status epileptics in the past 6 months. Seizures having a metabolic, neoplastic, or active infectious origin. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Seizures</keyword>
	<keyword>oxcarbazepine</keyword>
	<keyword>child</keyword>
</DOC>